Ibrutinib CAS 936563-96-1 Purity>99.5% (HPLC) API

Kufotokozera Kwachidule:

Dzina la Chemical: Ibrutinib

CAS: 936563-96-1

Kuyera:> 99.5% (HPLC)

Maonekedwe: Ufa Woyera mpaka Woyera wa Crystal

Ibrutinib ndi BTK inhibitor yomwe imagwiritsidwa ntchito pochiza Chronic Lymphocytic Leukemia (CLL) ndi Mantle Cell Lymphoma (MCL)

Lumikizanani ndi Dr. Alvin Huang

Mobile/Wechat/WhatsApp: +86-15026746401

E-Mail: alvin@ruifuchem.com

Titumizireni imelo

Tsatanetsatane wa Zamalonda

Zogwirizana nazo

Zolemba Zamalonda

Kufotokozera:

Zogwirizana ndi Ibrutinib:
(S)-1-Boc-3-Hydroxypiperidine CAS 143900-44-1
4-Phenoxyphenylboronic Acid CAS 51067-38-0
Ibrutinib Wapakatikati N-2 CAS 330786-24-8
Ibrutinib Wapakatikati N-3 CAS 330792-70-6
Ibrutinib CAS 936563-96-1

Chemical Properties:

Dzina la Chemical	Ibrutinib
Mawu ofanana ndi mawu	1- [(3R)-3--[4-Amino-3-(4-phenoxyphenyl)-1H-pyrazolo[3,4-d]pyrimidin-1-yl]-1-piperidinyl]-2-propen-1- chimodzi;PCI-32765
Nambala ya CAS	936563-96-1
Stock Status	Mu Stock, Kupanga Kukula Mpaka Matani
Molecular Formula	C25H24N6O2
Kulemera kwa Maselo	440.50
Mtundu	Ruifu Chemical

Zofotokozera:

Kanthu	Zofotokozera
Maonekedwe	Ufa Woyera mpaka Woyera wa Crystal
Chizindikiritso	IR;Mtengo wa HPLC
Kutaya pa Kuyanika	<0.50%
Zotsalira pa Ignition	≤0.10%
Zitsulo Zolemera (monga Pb)	≤20ppm
Chidetso Chilichonse Chilichonse	≤0.20%
Zonse Zonyansa	<0.50%
Kuyera / Kusanthula Njira	> 99.5% (HPLC)
Test Standard	Enterprise Standard
Kugwiritsa ntchito	API

Phukusi & Kusungira:

Phukusi: Botolo, Aluminiyamu zojambulazo thumba, 25kg/Cardboard Drum, kapena malinga ndi zofunika kasitomala.

Mkhalidwe Wosungira:Sungani muzitsulo zosindikizidwa pamalo ozizira ndi owuma;Tetezani ku kuwala ndi chinyezi.

Ubwino:

FAQ:

Ntchito:

Ibrutinib (CAS: 936563-96-1) ndi inhibitor ya Bruton tyrosine kinase (BTK) yochizira matenda a lymphocytic leukemia (CLL) ndi mantle cell lymphoma (MCL).Zonse ziwiri za MCL ndi CLL ndi za B-cell non-Hodgkin's lymphoma, yomwe imakhala yosasunthika komanso yomwe imakonda kubwereranso.Chemoimmunotherapy yomwe imagwiritsidwa ntchito nthawi zambiri siimayang'aniridwa, ndipo zotsatira zoyipa za giredi 3 kapena 4 zimachitika nthawi zambiri.Ibrutinib ikhoza kuphatikiza ndi BTK, yomwe ndi yofunikira pakupanga, kusiyanitsa, kulumikizana ndi kupulumuka kwa ma lymphocyte a B, ndikuletsa mosasinthika ntchito ya BTK, kuletsa kufalikira ndi kupulumuka kwa maselo otupa.Kuphatikiza apo, imayamwa mwachangu pambuyo pa makonzedwe amkamwa, kuchuluka kwambiri kwa plasma kumafika 1 ~ 2h, ndipo zotsatira zoyipa zimakhala giredi 1 kapena 2, yomwe idzakhala njira yatsopano yochizira CLL ndi MCL.Pa November 13, 2013, US FDA idzafulumizitsa kampani yovomerezeka ya Johnson & Johnson ndi United States Imbruvica (dzina lodziwika: Ibrutinib) pofuna kuchiza mantle cell lymphoma (MCL).Ibrutinib, idapatsidwa mwayi wopambana ndi FDA mu February 2013 ndipo idavomerezedwa ku MCL pa Novembara 13, 2013 ndi CLL pa February 12, 2014, motsatana.